IT - Software · Founded 2006 · www.ikshealth.com · BSE 544309 · NSE IKS · ISIN INE115Q01022
No Notes Added Yet
Business
Inventurus Knowledge Solutions Ltd. (IKS) is an India-based company primarily engaged in providing Business Process Management (BPM) and IT solutions, with a strong focus on the healthcare sector. Its core business model revolves around offering services, particularly Revenue Cycle Management (RCM), medical coding, medical billing, and other administrative and IT support services, predominantly to healthcare providers in the United States. The company makes money by charging fees for these outsourced services, which can be based on transaction volumes, a percentage of collections, or a retainer model, helping clients improve operational efficiency, reduce costs, and optimize revenue generation.
Revenue Mix
IKS's revenue is largely dominated by its healthcare-focused services. The primary segment is healthcare Revenue Cycle Management (RCM), which encompasses a suite of services from patient registration to final claim settlement. Within RCM, specific services would include medical coding, medical billing, accounts receivable follow-up, denial management, and payment posting. While specific percentage contributions are not publicly available, the vast majority of its revenue is derived from providing these specialized back-office and IT-enabled services to the US healthcare industry.
Industry
IKS operates in the highly competitive global IT-BPM industry, specifically within the healthcare vertical. The industry structure is characterized by a mix of large, diversified IT service providers with healthcare practices and niche, specialized healthcare BPO firms. The demand for outsourcing in healthcare is driven by increasing cost pressures, regulatory complexities (like HIPAA), and the need for operational efficiency among healthcare providers. IKS positions itself as a specialist in US healthcare RCM, leveraging deep domain expertise and a global delivery model (offshore in India for US clients). It competes with both large Indian IT service companies having healthcare segments and other pure-play healthcare RCM providers.
MOAT
IKS's primary competitive advantages include:
Domain Expertise: Deep understanding of the complex US healthcare regulatory environment, medical coding standards, and billing processes. This specialized knowledge is critical and difficult for generalist firms to replicate quickly.
Switching Costs: Once a healthcare provider integrates IKS's RCM services into its operations, the costs and disruption associated with switching to a new vendor (data migration, process re-engineering, staff training) are high, creating customer stickiness.
Operational Scale & Efficiency: Ability to process large volumes of transactions efficiently due to optimized workflows and potentially proprietary platforms, leading to cost advantages for clients.
Growth Drivers
Key factors that can drive IKS's growth over the next 3-5 years include:
Increasing Outsourcing Trend: Continued pressure on US healthcare providers to reduce costs and improve efficiency will drive further outsourcing of non-core functions like RCM.
Complexity of US Healthcare: Ever-evolving regulatory landscape and payment models in the US healthcare system necessitates specialized expertise that IKS provides.
Digital Transformation: Adoption of automation, AI, and analytics in RCM and other healthcare processes will create new service opportunities.
Aging Population & Healthcare Demand: An increasing aging population in the US implies higher healthcare utilization, leading to more RCM activity.
Service Expansion: Potential to expand into new adjacent healthcare IT/BPO services or deepen existing offerings with advanced analytics and AI.
Risks
Key business risks for IKS include:
US Healthcare Policy Changes: Any significant shifts in US healthcare regulations, reimbursement models (e.g., from fee-for-service to value-based care), or government spending could adversely impact demand for RCM services.
Intense Competition & Pricing Pressure: The IT-BPM sector is highly competitive, potentially leading to pricing pressures and margin erosion.
Client Concentration: Reliance on a few large clients could expose the company to significant revenue volatility if a major client is lost or scales down operations.
Talent Acquisition & Retention: Difficulty in attracting, training, and retaining skilled professionals (e.g., medical coders, IT specialists) is a constant challenge.
Data Security & Compliance: Handling sensitive patient health information (PHI) requires strict adherence to HIPAA and other data privacy regulations. Any breach or non-compliance could lead to severe penalties and reputational damage.
Technological Disruption: Rapid advancements in automation and AI could disrupt traditional BPO models, requiring continuous investment in new technologies.
Management & Ownership
As a listed Indian company, IKS typically has a promoter-driven management structure, where the founding family or individuals hold a significant ownership stake and play a crucial role in strategic direction. The management team likely possesses deep operational and domain expertise within the healthcare IT-BPM space, which is essential for navigating this specialized niche. Ownership is typically a mix of promoter holdings, institutional investors (both domestic and foreign), and public shareholders. Specific details on promoter names or their exact stake are not part of this general overview.
Outlook
IKS is strategically positioned in the resilient and growing healthcare IT-BPM sector, benefiting from the ongoing need for cost efficiency and specialized expertise among US healthcare providers. The company's deep domain knowledge in Revenue Cycle Management provides a strong foundation. The bull case hinges on continued expansion of outsourcing by healthcare organizations, successful adoption of new technologies like AI in RCM, and efficient execution in a competitive landscape. However, the bear case must consider the significant risks posed by potential changes in US healthcare policy, intense pricing competition, and the constant need to innovate and secure sensitive data. The company's future performance will depend on its ability to leverage its specialized expertise, adapt to technological shifts, and navigate the complex regulatory environment of the US healthcare market while maintaining client relationships.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 567 | 620 | 640 | 643 | 657 | 724 | 740 | 781 | 815 | 858 |
| Other Income | 6 | 15 | 4 | 5 | 27 | 3 | 3 | 4 | 6 | 5 |
| Total Income | 573 | 635 | 644 | 648 | 684 | 727 | 743 | 785 | 821 | 863 |
| Total Expenditure | 405 | 494 | 467 | 454 | 476 | 498 | 502 | 509 | 533 | 557 |
| Operating Profit | 168 | 140 | 177 | 194 | 208 | 229 | 241 | 275 | 287 | 305 |
| Interest | 26 | 32 | 26 | 22 | 21 | 21 | 18 | 16 | 23 | 13 |
| Depreciation | 19 | 27 | 28 | 28 | 28 | 28 | 28 | 30 | 32 | 34 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 124 | 81 | 122 | 144 | 160 | 180 | 195 | 229 | 232 | 258 |
| Provision for Tax | 22 | 17 | 27 | 31 | 30 | 32 | 43 | 47 | 46 | 47 |
| Profit After Tax | 102 | 64 | 95 | 113 | 130 | 148 | 152 | 182 | 186 | 211 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -2 | -5 |
| Profit After Adjustments | 102 | 64 | 95 | 113 | 130 | 148 | 152 | 181 | 183 | 206 |
| Adjusted Earnings Per Share | 6 | 3.8 | 5.6 | 6.7 | 7.6 | 8.7 | 8.8 | 10.6 | 10.7 | 12.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 191 | 291 | 351 | 397 | 503 | 529 | 553 | 764 | 1031 | 1818 | 2664 | 3194 |
| Other Income | 0 | 1 | 3 | 12 | 23 | 32 | 16 | 21 | 29 | 40 | 40 | 18 |
| Total Income | 191 | 292 | 354 | 409 | 527 | 561 | 569 | 784 | 1060 | 1858 | 2704 | 3212 |
| Total Expenditure | 164 | 232 | 305 | 352 | 393 | 368 | 348 | 466 | 639 | 1297 | 1894 | 2101 |
| Operating Profit | 27 | 60 | 49 | 57 | 134 | 192 | 221 | 319 | 421 | 561 | 810 | 1108 |
| Interest | 9 | 9 | 7 | 6 | 5 | 7 | 8 | 7 | 6 | 61 | 91 | 70 |
| Depreciation | 6 | 10 | 16 | 28 | 33 | 41 | 30 | 23 | 25 | 59 | 113 | 124 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20 | -31 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 41 | 26 | 22 | 97 | 145 | 183 | 269 | 359 | 442 | 606 | 914 |
| Provision for Tax | 2 | 2 | 3 | 4 | 4 | 7 | 17 | 36 | 54 | 71 | 120 | 183 |
| Profit After Tax | 11 | 39 | 23 | 18 | 93 | 137 | 165 | 233 | 305 | 370 | 486 | 731 |
| Adjustments | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8 |
| Profit After Adjustments | 11 | 39 | 23 | 18 | 93 | 137 | 165 | 233 | 305 | 370 | 486 | 722 |
| Adjusted Earnings Per Share | 0.7 | 2.4 | 1.4 | 1.1 | 5.8 | 8.4 | 10.1 | 13.7 | 18.1 | 21.9 | 28.6 | 42.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 47% | 52% | 38% | 30% |
| Operating Profit CAGR | 44% | 36% | 33% | 41% |
| PAT CAGR | 31% | 28% | 29% | 46% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 4% | NA% | NA% | NA% |
| ROE Average | 34% | 38% | 40% | 122% |
| ROCE Average | 29% | 37% | 42% | 44% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | -17 | 25 | 54 | 82 | 200 | 283 | 457 | 647 | 829 | 1158 | 1790 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 37 | 56 | 23 | 10 | 1 | 0 | 0 | 0 | 0 | 812 | 509 |
| Other Non-Current Liabilities | 1 | 2 | 4 | -2 | -11 | 22 | 9 | -19 | -50 | 92 | 86 |
| Total Current Liabilities | 59 | 67 | 80 | 90 | 50 | 81 | 59 | 83 | 115 | 881 | 651 |
| Total Liabilities | 80 | 150 | 161 | 181 | 240 | 386 | 524 | 711 | 894 | 2943 | 3036 |
| Fixed Assets | 17 | 34 | 43 | 80 | 52 | 98 | 87 | 76 | 59 | 1833 | 1790 |
| Other Non-Current Assets | 20 | 43 | 61 | 12 | 12 | 55 | 93 | 174 | 137 | 213 | 462 |
| Total Current Assets | 44 | 73 | 56 | 88 | 175 | 233 | 345 | 461 | 698 | 898 | 784 |
| Total Assets | 80 | 150 | 161 | 181 | 240 | 386 | 524 | 711 | 894 | 2943 | 3036 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 3 | 15 | 6 | 6 | 38 | 82 | 53 | 146 | 124 | -23 |
| Cash Flow from Operating Activities | 18 | 53 | 45 | 45 | 97 | 163 | 175 | 233 | 288 | 210 | 318 |
| Cash Flow from Investing Activities | -22 | -39 | -35 | -29 | -13 | -80 | -166 | -82 | -156 | -1141 | 244 |
| Cash Flow from Financing Activities | 5 | -2 | -18 | -16 | -52 | -41 | -37 | -59 | -152 | 780 | -389 |
| Net Cash Inflow / Outflow | 1 | 12 | -9 | -0 | 32 | 42 | -27 | 92 | -20 | -151 | 173 |
| Closing Cash & Cash Equivalent | 3 | 15 | 6 | 6 | 38 | 82 | 53 | 146 | 124 | -23 | 146 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.68 | 2.39 | 1.4 | 1.15 | 5.77 | 8.45 | 10.1 | 13.72 | 18.13 | 21.9 | 28.55 |
| CEPS(Rs) | 1.06 | 3.02 | 2.38 | 2.9 | 7.81 | 10.94 | 11.95 | 15.1 | 19.59 | 25.35 | 35.17 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 1.19 | 1.19 | 5.4 | 10 | 10 | 0 |
| Book NAV/Share(Rs) | -1.09 | 1.55 | 3.27 | 4.94 | 11.82 | 16.91 | 27.35 | 37.66 | 48.94 | 67.66 | 102.96 |
| Core EBITDA Margin(%) | 14.01 | 20.27 | 13.11 | 11.29 | 22.01 | 30.35 | 37.01 | 39.01 | 38.01 | 28.67 | 28.91 |
| EBIT Margin(%) | 11.06 | 16.97 | 9.29 | 7.2 | 20.15 | 28.72 | 34.45 | 36.1 | 35.43 | 27.66 | 26.19 |
| Pre Tax Margin(%) | 6.54 | 14 | 7.42 | 5.57 | 19.24 | 27.35 | 33.06 | 35.16 | 34.84 | 24.3 | 22.76 |
| PAT Margin (%) | 5.6 | 13.43 | 6.65 | 4.65 | 18.51 | 25.99 | 29.93 | 30.51 | 29.6 | 20.38 | 18.25 |
| Cash Profit Margin (%) | 8.66 | 17 | 11.3 | 11.74 | 25.04 | 33.64 | 35.42 | 33.56 | 31.98 | 23.6 | 22.47 |
| ROA(%) | 13.31 | 33.91 | 15 | 10.79 | 44.24 | 43.89 | 36.34 | 37.73 | 38.06 | 19.31 | 16.26 |
| ROE(%) | 0 | 929.34 | 58.45 | 27.57 | 68.97 | 59.01 | 45.74 | 42.85 | 41.72 | 37.63 | 33.55 |
| ROCE(%) | 36.17 | 60.44 | 29.33 | 22.73 | 60.07 | 62.42 | 51.44 | 49.95 | 49.52 | 31.77 | 28.65 |
| Receivable days | 71.51 | 53.27 | 46 | 45.45 | 44.61 | 48.18 | 49.37 | 40.74 | 45.34 | 52.46 | 61.24 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.15 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.41 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.81 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.42 | 0.25 | 0.19 | 0.14 | -0.07 | -0.22 | -0.39 | -0.43 | -0.49 | 0.48 | 9.95 |
| EV/Core EBITDA(x) | 2.96 | 1.22 | 1.33 | 0.96 | -0.25 | -0.59 | -0.98 | -1.04 | -1.2 | 1.54 | 32.71 |
| Net Sales Growth(%) | 0 | 52.33 | 20.41 | 13.08 | 26.91 | 5.08 | 4.45 | 38.2 | 35.05 | 76.28 | 46.54 |
| EBIT Growth(%) | 0 | 133.61 | -34.09 | -12.34 | 255.11 | 49.8 | 25.28 | 44.82 | 32.55 | 37.59 | 38.78 |
| PAT Growth(%) | 0 | 265.06 | -40.33 | -20.98 | 405.05 | 47.55 | 20.31 | 40.87 | 31.02 | 21.38 | 31.2 |
| EPS Growth(%) | 0 | 248.98 | -41.29 | -18.12 | 403.05 | 46.35 | 19.5 | 35.92 | 32.1 | 20.77 | 30.41 |
| Debt/Equity(x) | -4.41 | 3.13 | 1.15 | 0.66 | 0.02 | 0 | 0 | 0 | 0 | 1.03 | 0.42 |
| Current Ratio(x) | 0.74 | 1.09 | 0.7 | 0.98 | 3.52 | 2.88 | 5.86 | 5.56 | 6.07 | 1.02 | 1.2 |
| Quick Ratio(x) | 0.74 | 1.09 | 0.7 | 0.98 | 3.52 | 2.88 | 5.86 | 5.56 | 6.07 | 1.02 | 1.2 |
| Interest Cover(x) | 2.45 | 5.72 | 4.98 | 4.42 | 22.22 | 20.97 | 24.78 | 38.54 | 60.37 | 8.23 | 7.63 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 63.72 | 63.72 | 63.72 | 63.72 | 63.72 | 63.72 |
| FII | 5.47 | 5.37 | 6.5 | 7.02 | 7.56 | 8.19 |
| DII | 4.42 | 4.04 | 4.33 | 4.89 | 6.06 | 6.4 |
| Public | 26.39 | 26.86 | 25.45 | 24.37 | 22.66 | 21.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 10.93 | 10.93 | 10.93 | 10.93 | 10.93 | 10.93 |
| FII | 0.94 | 0.92 | 1.11 | 1.2 | 1.3 | 1.4 |
| DII | 0.76 | 0.69 | 0.74 | 0.84 | 1.04 | 1.1 |
| Public | 4.53 | 4.61 | 4.37 | 4.18 | 3.89 | 3.72 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17.16 | 17.16 | 17.16 | 17.16 | 17.16 | 17.16 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +47% | +52% | +38% | +30% |
| Operating Profit CAGR | +44% | +36% | +33% | +41% |
| PAT CAGR | +31% | +28% | +29% | +46% |
| Share Price CAGR | +4% | — | — | — |
| ROE Average | +34% | +38% | +40% | +122% |
| ROCE Average | +29% | +37% | +42% | +44% |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 63.72 | 63.72 | 63.72 | 63.72 | 63.72 | 63.72 |
| FII | 5.47 | 5.37 | 6.5 | 7.02 | 7.56 | 8.19 |
| DII | 4.42 | 4.04 | 4.33 | 4.89 | 6.06 | 6.4 |
| Public | 36.28 | 36.28 | 36.28 | 36.28 | 36.28 | 36.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 10.93 | 10.93 | 10.93 | 10.93 | 10.93 | 10.93 |
| FII | 0.94 | 0.92 | 1.11 | 1.2 | 1.3 | 1.4 |
| DII | 0.76 | 0.69 | 0.74 | 0.84 | 1.04 | 1.1 |
| Public | 6.22 | 6.22 | 6.22 | 6.22 | 6.22 | 6.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17.16 | 17.16 | 17.16 | 17.16 | 17.16 | 17.16 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.